Efficacy and safety of single-dose DFN-15 for treatment of acute postsurgical dental pain: a randomized, double-blind, placebo-controlled study
| Autor: | Neil Singla, Todd Bertoch, Sagar Munjal, Srinivas Shenoy |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Analgesic Placebo-controlled study macromolecular substances Placebo Double-Blind Method Clinical endpoint Humans Medicine Adverse effect Pain Measurement Analgesics Pain Postoperative business.industry Dental pain Acetaminophen stomatognathic diseases Anesthesiology and Pain Medicine Neurology Celecoxib Anesthesia Neurology (clinical) Analgesia business Oxycodone Research Paper medicine.drug |
| Zdroj: | Pain |
| ISSN: | 1872-6623 0304-3959 |
| DOI: | 10.1097/j.pain.0000000000002312 |
| Popis: | A single dose of DFN-15 up to 250 mg, a celecoxib oral solution, effectively treated moderate to severe pain after a dental surgery. The analgesic efficacy and safety of DFN-15, a new oral liquid formulation of celecoxib with more rapid absorption than the capsule, were evaluated in the treatment of acute pain in adult patients after dental surgery. In this randomized, double-blind, placebo-controlled, dose-ranging study, 120 otherwise healthy adults who underwent the extraction of bilateral impacted mandibular third molar teeth and experienced moderate to severe pain postsurgery were randomly assigned, in a 1:1:1:1 ratio, to receive one dose of either placebo or DFN-15 at 3 doses: 62.5, 125, and 250 mg. Participants were evaluated at prespecified time points over 8 hours after study drug administration, using several instruments, including the 11-point Numerical Pain Rating Scale, 5-point Pain Relief Scale, and 5-point Treatment Satisfaction Scale. Rescue analgesic (oxycodone / acetaminophen) was permitted. The primary endpoint was the summed pain intensity difference (SPID) over the 6-hour postdose period (SPID6), which was compared between each DFN-15 dose and placebo using analysis of covariance. Other assessments of pain relief, use of rescue medication, and safety were also analyzed. All 3 doses of DFN-15 were significantly superior to placebo in SPID6 (least square mean difference over placebo: −756.6, −1120.7, and −1355.1, P < 0.0001 for all comparisons). In addition, DFN-15 was generally superior to placebo in other endpoints, including reduction of pain intensity, speed and magnitude of pain relief, treatment satisfaction, and rescue medication use. DFN-15 was similar to placebo in the incidence of adverse events with no apparent dose-related effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|